Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

聯康集團
Uni-Bio Science

UNI-BIO SCIENCE GROUP LIMITED

聯康生物科技集團有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0690)

PROFIT WARNING

This announcement is made by Uni-Bio Science Group Limited (the "**Company**", together with its subsidiaries and consolidated affiliated entities, the "**Group**") in accordance with Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board (the "**Board**") of directors (the "**Director(s)**") of the Company wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 (the "**Reporting Period**") and the information currently available to the Board, it is expected that the Group will record a net profit of approximately HK$30 million in the Reporting Period, as compared with a net profit of approximately HK$75.96 million for the six months ended 30 June 2025 (the "**Corresponding Period**").

Based on the information currently available, the Board considers that the Group's results for the Reporting Period decrease in profit, which was mainly attributable to the following factors: First, the newly implemented Value-Added Tax Law of the PRC in this year has abolished the option for biological products to apply the simplified taxation method at 3%, and VAT is required to be calculated and paid at the general rate of 13%. Such adjustment has had a certain impact on the Group's biological drug business, covering products including GeneTime, GeneSoft and Bogutai. Second, certain drugs selected under the volume-based procurement programme will be sold at the new bid-winning prices. Third, the increase in R&D expenditure and BD-related costs. The Group has intensified its investment in the development of innovative regenerative medicine projects, being its second growth driver, accelerated the advancement of international commercialization, and established a dedicated BD team to broaden its product pipeline, and the above increased expenses are the Group's forward-looking strategic investments in its innovation-driven transformation and global expansion, and will weigh on short-term profitability, but they are expected to enhance the Group's competitiveness in international markets and sustainable growth potential in the medium-to-long term. As of 30 June 2026, the Group's financial position and cash flow remain very stable and are sufficient to support the needs of the Group's various businesses, with cash and cash equivalents of not less than HK$140,000,000.

The information contained in this announcement is only based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the Reporting Period and the information currently available to the Board, and is not based on any information or figures which have been audited or reviewed by the Company's auditor and may be subject to possible adjustments. The Group is in the process of finalizing the interim results of the Group for the Reporting Period, and the actual results of the Group for the Reporting Period may differ from what is disclosed in this announcement. Shareholders and potential investors are advised to read carefully the Company's interim results announcement for the six months ended 30 June 2026, which will be published on 26 August 2026.

Shareholders and potential investors should exercise caution when investing or dealing in the shares of the Company.

On behalf of the Board
Uni-Bio Science Group Limited
Kingsley Leung
Chairman

Hong Kong, 7 August 2026

As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Kingsley Leung (Chairman), Mr. Chen Dawei (Vice-Chairman), Mr. Zhao Zhi Gang (Chief executive) and Dr. Wen Yalei (Chief Operating Officer); two non-executive Directors, Mr. Yau Kwok Wing Tony and Ms. Zhang Qing; and three independent non-executive Directors, namely, Mr. Chow Kai Ming, Mr. Ren Qimin and Mr. Ma Qingshan.

* *For identification purposes only*